CompletedNCT04605393
CBD and the effects of cannabis in people with schizophrenia
About this title
Read the official source — NCT04605393Medication studyAges 18–65United Kingdom
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- LondonSee all locations and recruitment
Study information
Study start dateStarted: January 1, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 36
- Sponsor
- King's College London
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Locations
- United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04605393
- Official title
Show the full official title
Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
London
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is King's College London, a university.
Did this study involve medication?
Yes. The study involved medication, including Cannabidiol, Placebo and Delta-9-THC.
Who was this study for?
Listed age limits: 18 years to 65 years.
